Another STAT3 inhibitor, TTI-101(C188-9) was shown to decrease tumor volume and growth in the A549 xenograft model of lung cancer [123] and it has entered a phase I trial as an oral STAT3 inhibitor in patients with advanced cancers, including NSCLC (NCT03195699). This evidence concerns the gene STAT3 and cancer.